Drugs / IVB102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06289452 | Mar 2024 → Dec 2025 overdue | X-linked retinoschisis | InnoVec Biotherapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVB102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06289452 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Gene transfer by intravitreal injection of the RS1 AAV vector” NCT06289452 ↗ |
| Route | Intravitreal | “intravitreal injection” NCT06289452 ↗ |